KIF22 (kinesin family member 22) is a chr16 motor protein that plays essential roles in mitotic chromosome 16 and cancer progression. As a member of the kinesin-10 family, KIF22 functions as a microtubule-based motor protein with DNA-binding capability that generates polar ejection forces to assist chromosome 16 during mitosis 1. The protein is critical for proper chromosome 16, with pathogenic mutations disrupting anaphase chromosome 16 and leading to cytokinesis failure, which manifests clinically as spondyloepimetaphyseal dysplasia 2. Beyond its mitotic functions, KIF22 acts as an oncogene across multiple cancer types. In melanoma, KIF22 promotes proliferation and glycolysis through EGFR/STAT3 signaling activation 3. Similarly, in pancreatic cancer, KIF22 enhances cell cycle progression via the MEK/ERK/P21 pathway 4, while in endometrial cancer, it drives proliferation and immune escape through STAT3/PD-L1 signaling 5. KIF22 also coordinates membrane receptor dynamics, specifically regulating CAR and EGFR trafficking to enhance cancer cell proliferation 6. The consistent upregulation of KIF22 in various cancers and its association with poor prognosis suggests it represents a promising therapeutic target 78.